Date: 2015-07-10
Type of information: Private placement
Company: Clovis Oncology (USA - CO)
Investors:
Amount: $275 million
Funding type: private placement
Planned used: Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including commercial planning and sales and marketing expenses associated with the potential launches of rociletinib and rucaparib, if approved by the FDA and the European Medicines Agency (EMA) in the United States and the European Union, respectively, funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.
Others: * On July 10, 2015, Clovis Oncology announced that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 528,846 shares. The offering, including the sale of the additional shares, is expected to close on July 14, 2015, subject to customary closing conditions. The shares of Clovis Oncology common stock described above were offered only by means of a prospectus supplement and related prospectus pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. * On July 8, 2015, Clovis Oncology announced the pricing of an underwritten public offering of 3,525,641 shares of its common stock at $78.00 per share, before underwriting discounts and commissions. In addition, the underwriters have a 30-day option to purchase up to an additional 528,846 shares of common stock from Clovis Oncology on the same terms and conditions. The offering is expected to close on July 14, 2015, subject to customary closing conditions. J. P. Morgan Securities LLC is acting as lead book-running manager and representative of the underwriters for the offering. Credit Suisse Securities (USA) LLC is also acting as a joint book-runner, and Stifel and Mizuho Securities are acting as co-managers for the offering. * On July 7, 2015, Clovis Oncology announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $275 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology. J. P. Morgan Securities LLC is acting as lead book-running manager and representative of the underwriters for the offering. Credit Suisse Securities (USA) LLC is also acting as a joint book-runner, and Stifel and Mizuho Securities are acting as co-managers for the offering. In addition, Clovis Oncology intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. This offering is being made only by means of a prospectus supplement and related prospectus. Copies of the prospectus supplement and related prospectus relating to this offering may be obtained from J. P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204.
Therapeutic area: Cancer - Oncology
